187 related articles for article (PubMed ID: 18331599)
1. FOXP3 positive regulatory T-cells in cutaneous and systemic CD30 positive T-cell lymphoproliferations.
Gjerdrum LM; Woetmann A; Odum N; Hother C; Henrik-Nielsen R; Gniadecki R; Ralfkiaer E
Eur J Haematol; 2008 Jun; 80(6):483-9. PubMed ID: 18331599
[TBL] [Abstract][Full Text] [Related]
2. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
Benner MF; Jansen PM; Meijer CJ; Willemze R
Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
[TBL] [Abstract][Full Text] [Related]
4. ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review.
ten Berge RL; Oudejans JJ; Ossenkoppele GJ; Meijer CJ
J Pathol; 2003 May; 200(1):4-15. PubMed ID: 12692835
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease.
Vermeer MH; Dukers DF; ten Berge RL; Bloemena E; Wu L; Vos W; de Vries E; Tensen CP; Meijer CJ; Willemze R
Mod Pathol; 2002 Aug; 15(8):838-44. PubMed ID: 12181269
[TBL] [Abstract][Full Text] [Related]
6. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders.
Yamaguchi T; Ohshima K; Karube K; Kawano R; Nakayama J; Suzumiya J; Kikuchi M
Br J Dermatol; 2006 May; 154(5):904-9. PubMed ID: 16634894
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous CD30-positive lymphoproliferative disorders with CD8 expression: a clinicopathologic study of 21 cases.
Plaza JA; Feldman AL; Magro C
J Cutan Pathol; 2013 Feb; 40(2):236-47. PubMed ID: 23189966
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis in CD30-positive lymphoproliferative disorders of the skin.
Greisser J; Doebbeling U; Roos M; Mueller B; Schmid M; Burg G; Kadin ME; Kempf W
Exp Dermatol; 2005 May; 14(5):380-5. PubMed ID: 15854132
[TBL] [Abstract][Full Text] [Related]
9. Abnormal activator protein 1 transcription factor expression in CD30-positive cutaneous large-cell lymphomas.
Mao X; Orchard G; Russell-Jones R; Whittaker S
Br J Dermatol; 2007 Nov; 157(5):914-21. PubMed ID: 17725669
[TBL] [Abstract][Full Text] [Related]
10. The role of p53 and anaplastic lymphoma kinase genes in the progression of cutaneous CD30(+) lymphoproliferative diseases.
Kapur S; Tiemann M; Menke MA; Schubert C; Parwaresch R
Indian J Med Res; 2005 Jan; 121(1):46-54. PubMed ID: 15713979
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea.
Kim YC; Yang WI; Lee MG; Kim SN; Cho KH; Lee SJ; Lee MW; Koh JK
Int J Dermatol; 2006 Nov; 45(11):1312-6. PubMed ID: 17076712
[TBL] [Abstract][Full Text] [Related]
12. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders.
Drakos E; Leventaki V; Schlette EJ; Jones D; Lin P; Medeiros LJ; Rassidakis GZ
Am J Surg Pathol; 2007 Mar; 31(3):447-53. PubMed ID: 17325487
[TBL] [Abstract][Full Text] [Related]
13. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival.
Gjerdrum LM; Woetmann A; Odum N; Burton CM; Rossen K; Skovgaard GL; Ryder LP; Ralfkiaer E
Leukemia; 2007 Dec; 21(12):2512-8. PubMed ID: 17713545
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the tumor microenvironment in primary cutaneous CD30-positive lymphoproliferative disorders: a predominance of CD163-positive M2 macrophages.
De Souza A; Tinguely M; Burghart DR; Berisha A; Mertz KD; Kempf W
J Cutan Pathol; 2016 Jul; 43(7):579-88. PubMed ID: 27080437
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of FoxP3 expression in peripheral T-cell lymphoma.
Bonzheim I; Geissinger E; Tinguely M; Roth S; Grieb T; Reimer P; Wilhelm M; Rosenwald A; Müller-Hermelink HK; Rüdiger T
Am J Clin Pathol; 2008 Oct; 130(4):613-9. PubMed ID: 18794055
[TBL] [Abstract][Full Text] [Related]
16. Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders.
Samols MA; Su A; Ra S; Cappel MA; Louissant A; Knudson RA; Ketterling RP; Said J; Binder S; Harris NL; Feldman AL; Kim J; Kim YH; Gratzinger D
Am J Surg Pathol; 2014 Sep; 38(9):1203-11. PubMed ID: 24805854
[TBL] [Abstract][Full Text] [Related]
17. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.
Miracco C; Mourmouras V; Biagioli M; Rubegni P; Mannucci S; Monciatti I; Cosci E; Tosi P; Luzi P
Oncol Rep; 2007 Nov; 18(5):1115-22. PubMed ID: 17914561
[TBL] [Abstract][Full Text] [Related]
18. Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders.
Greisser J; Palmedo G; Sander C; Kutzner H; Kazakov DV; Roos M; Burg G; Kempf W
J Cutan Pathol; 2006 Nov; 33(11):711-5. PubMed ID: 17083688
[TBL] [Abstract][Full Text] [Related]
19. CD30-positive T-cell lymphoproliferative disorder of the oral mucosa--an indolent lesion: report of 4 cases.
Agarwal M; Shenjere P; Blewitt RW; Hall G; Sloan P; Pigadas N; Banerjee SS
Int J Surg Pathol; 2008 Jul; 16(3):286-90. PubMed ID: 18387994
[TBL] [Abstract][Full Text] [Related]
20. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators.
Kempf W
J Cutan Pathol; 2006 Feb; 33 Suppl 1():58-70. PubMed ID: 16412214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]